President Trump's $500 billion Stargate Initiative to build AI infrastructure faces blowback from his conspiracist supporters ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

There are 20 cell and gene therapies on Europe's market versus 43 in the U.S. Find out more about this ecosystem.

The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

We recently published a list of These 10 Firms Were Thursday’s Top Performers. In this article, we are going to take a look ...

Following the lead of previous work on mRNA-based vaccines, therapies for spinal cord injuries and more, the method relies upon mineral-coated microparticles to deliver mRNA that encodes for ...

The Kowalinski group at EMBL Grenoble discovered notable differences between the nuclear cap-binding complex in trypanosomes and humans, a critical component in cellular RNA metabolism. Trypanosomes ...